C
DSGN icon

Covestor’s Design Therapeutics DSGN Stock Holding History

Covestor’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-20
Closed – – 2330
2024
Q3 		$0 Sell
20
-2
-9% -$9 ﹤0.01% 2319
2024
Q2 		$0 Sell
22
-10
-31% -$39 ﹤0.01% 2333
2024
Q1 		$0 Sell
32
-2
-6% -$5 ﹤0.01% 2332
2023
Q4 		$0 Buy
34
+17
+100% +$39 ﹤0.01% 2245
2023
Q3 		$0 Sell
17
-3
-15% -$14 ﹤0.01% 2222
2023
Q2 		$0 Buy
20
+12
+150% +$73 ﹤0.01% 2231
2023
Q1 		$0 Hold
8
– – ﹤0.01% 2134
2022
Q4 		$0 Buy
8
+3
+60% +$41 ﹤0.01% 2167
2022
Q3 		$0 Buy
+5
New +$100 ﹤0.01% 2110

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Covestor's DSGN Position: Q4 2024 in Review

Covestor sold out of Design Therapeutics (DSGN) in Q4 2024, closing a stake of 20 shares.

Covestor first reported a position in DSGN in Q3 2022 and held it in 9 quarters. The position peaked at $0 in Q3 2024. 95 funds tracked by Wall St. Rank hold DSGN as of Q4 2024.

  • Covestor reported no remaining Design Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Covestor sold 20 Design Therapeutics shares in Q4 2024.
  • Covestor first reported a position in Design Therapeutics in Q3 2022 and held it in 9 quarters.
  • Covestor's Design Therapeutics position peaked at $0 in Q3 2024.
  • 95 funds tracked by Wall St. Rank held Design Therapeutics as of Q4 2024.

Based on Covestor's 13F filing for Q4 2024, filed 13 Feb 2025.